Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.

Fiche publication

Date publication

décembre 2025

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Dr CHAIGNEAU Loïc , Dr MENEVEAU Nathalie , Pr CURTIT Elsa , Dr MANSI Laura , Dr VERNEREY Dewi , Mr BOISSON Cyril , Mme MEURISSE Aurélia

Tous les auteurs :
Dutheil J, Pereira V, Boisson C, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Viot J, Meynard G, Goujon M, Dalens L, Dubourd C, Marchi S, Meneveau N, Vernerey D, Adotévi O, Meurisse A, Curtit E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41444692

Résumé

Everolimus was approved in 2012 for the treatment of advanced hormone-receptor-positive, HER2-negative metastatic breast cancer (MBC) in combination with exemestane. Since then, the first line treatment for these cancers has evolved with the development of CDK4/6 inhibitors.